Gene expression and epigenetic profiles of mammary gland tissue: Insight into the differential predisposition of four rat strains to mammary gland cancer

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 779, Issue , 2015, Pages 39-56

  Luzhna, Lidia ^a   Kutanzi, Kristy ^a   Kovalchuk, Olga ^a  

^a UNIVERSITY OF LETHBRIDGE   (Canada)

Author keywords

DNA methylation; Epigenetics; Gene expression profile; Histone modifications; Mammary cancer; Susceptibility

Indexed keywords

CHEMOKINE; COMPLEMENT; CYTOCHROME P450; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; GENOMIC DNA; GLUTATHIONE; HISTONE H3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUGUST COPENHAGEN IRISH RAT; BREAST CANCER; BREAST EPITHELIUM CELL; CANCER GENETICS; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CHROMATIN STRUCTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; FISCHER 344 RAT; FOCAL ADHESION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLUTATHIONE METABOLISM; HISTONE ACETYLATION; HISTONE METHYLATION; HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; LONG EVANS RAT; MAMMARY GLAND; METASTASIS; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RIBOSOME; RNA ISOLATION; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; STRAIN DIFFERENCE; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; EXPERIMENTAL MAMMARY NEOPLASM; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PATHOLOGY; UDDER;

RATTUS;

ANIMALS; DISEASE MODELS, ANIMAL; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED F344; RATS, LONG-EVANS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTOME;

EID: 84924672284     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2014.07.006     Document Type: Article

References (173)

1. World Health Organization World Health Report 2003.
2. Walton J.R., Buckley I.K. Cell models in the study of mechanisms of toxicity. Agents Actions 1975, 5:69-88.
3. Crocker T.T. The scientific imperative for use of human cells and organs in vitro: comp arative toxicology and oncogenesis. In Vitro 1977, 13:648-661.
4. Russell J.C. Of mice and men, rats and atherosclerosis. Cardiovasc. Res. 2003, 59:810-811.
5. Shull J.D. The rat oncogenome: comparative genetics and genomics of rat models of mammary carcinogenesis. Breast Dis. 2007, 28:69-86.
6. Shull J.D., Pennington K.L., Reindl T.M., Snyder M.C., Strecker T.E., Spady T.J., Tochacek M., McComb R.D. Susceptibility to estrogen-induced mammary cancer segregates as an incompletely dominant phenotype in reciprocal crosses between the ACI and Copenhagen rat strains. Endocrinology 2001, 142:5124-5130.
7. Harvell D.M., Strecker T.E., Tochacek M., Xie B., Pennington K.L., McComb R.D., Roy S.K., Shull J.D. Rat strain-specific actions of 17beta-estradiol in the mammary gland: correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogen-induced mammary cancers. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2779-2784.
8. Blankenstein M.A., Broerse J.J., de Vries J.B., van den Berg K.J., Knaan S., van der Molen H.J. The effect of subcutaneous administration of oestrogens on plasma oestrogen levels and tumour incidence in female rats. Eur. J. Cancer 1977, 13:1437-1443.
9. Vogel H.H., Turner J.E. Genetic component in rat mammary carcinogenesis. Radiat. Res. 1982, 89:264-273.
10. Stone J.P., Holtzman S., Shellabarger C.J. Neoplastic responses and correlated plasma prolactin levels in diethylstilbestrol-treated ACI and Sprague-Dawley rats. Cancer Res. 1979, 39:773-778.
11. Shellabarger C.J., Stone J.P., Holtzman S. Rat differences in mammary tumor induction with estrogen and neutron radiation. J. Natl. Cancer Inst. 1978, 61:1505-1508.
12. Broerse J.J., Hennen L.A., van Zwieten M.J. Radiation carcinogenesis in experimental animals and its implications for radiation protection. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 1985, 48:167-187.
13. Tennekes H., Kaufmann W., Dammann M., van Ravenzwaay B. The stability of historical control data for common neoplasms in laboratory rats and the implications for carcinogenic risk assessment. Regul. Toxicol. Pharmacol. 2004, 40:293-304.
14. Tennekes H., Gembardt C., Dammann M., van Ravenzwaay B. The stability of historical control data for common neoplasms in laboratory rats: adrenal gland (medulla), mammary gland, liver, endocrine pancreas, and pituitary gland. Regul. Toxicol. Pharmacol. 2004, 40:18-27.
15. Noble R.L., Cutts J.H. Mammary tumors of the rat: a review. Cancer Res. 1959, 19:1125-1139.
16. Okada M., Takeuchi J., Sobue M., Kataoka K., Inagaki Y., Shigemura M., Chiba T. Characteristics of 106 spontaneous mammary tumours appearing in Sprague-Dawley female rats. Br. J. Cancer 1981, 43:689-695.
17. Haseman J.K., Huff J.E., Rao G.N., Eustis S.L. Sources of variability in rodent carcinogenicity studies. Fundam. Appl. Toxicol. 1989, 12:793-804.
18. Dunning W.F., Curtis M.R., Segaloff A. Strain differences in response to estrone and the induction of mammary gland, adrenal, and bladder cancer in rats. Cancer Res. 1953, 13:147-152.
19. Szpirer C., Szpirer J. Mammary cancer susceptibility: human genes and rodent models. Mamm. Genome 2007, 18:817-831.
20. Rees E.D., Shick A.E., Christian J.C., Pugh J.R. Karyotypes of rats from strains of different susceptibility to mammary cancer induction. Cancer Res. 1968, 28:823-830.
21. Schaffer B.S., Lachel C.M., Pennington K.L., Murrin C.R., Strecker T.E., Tochacek M., Gould K.A., Meza J.L., McComb R.D., Shull J.D. Genetic bases of estrogen-induced tumorigenesis in the rat: mapping of loci controlling susceptibility to mammary cancer in a Brown Norway×ACI intercross. Cancer Res. 2006, 66:7793-7800.
22. Gould K.A., Tochacek M., Schaffer B.S., Reindl T.M., Murrin C.R., Lachel C.M., VanderWoude E.A., Pennington K.L., Flood L.A., Bynote K.K., Meza J.L., Newton M.A., Shull J.D. Genetic determination of susceptibility to estrogen-induced mammary cancer in the ACI rat: mapping of Emca1 and Emca2 to chromosomes 5 and 18. Genetics 2004, 168:2113-2125.
23. Milsted A., Marcelo M.C., Turner M.E., Ely D.L. Female Wistar-Kyoto and SHR/y rats have the same genotype but different patterns of expression of renin and angiotensinogen genes. J. Hypertens. 1998, 16:823-828.
24. Vo A.T., Millis R.M. Epigenetics and breast cancers. Obstet. Gynecol. Int. 2012, 2012:602720.
25. Fuks F. DNA methylation and histone modifications: teaming up to silence genes. Curr. Opin. Genet. Dev. 2005, 15:490-495.
26. Turker M.S., Bestor T.H. Formation of methylation patterns in the mammalian genome. Mutat. Res. 1997, 386:119-130.
27. Gama-Sosa M.A., Midgett R.M., Slagel V.A., Githens S., Kuo K.C., Gehrke C.W., Ehrlich M. Tissue-specific differences in DNA methylation in various mammals. Biochim. Biophys. Acta 1983, 740:212-219.
28. Raiche J., Rodriguez-Juarez R., Pogribny I., Kovalchuk O. Sex- and tissue-specific expression of maintenance and de novo DNA methyltransferases upon low dose X-irradiation in mice. Biochem. Biophys. Res. Commun. 2004, 325:39-47.
29. Rothenburg S., Koch-Nolte F., Thiele H.G., Haag F. DNA methylation contributes to tissue- and allele-specific expression of the T-cell differentiation marker RT6. Immunogenetics 2001, 52:231-241.
30. Holliday R., Pugh J.E. DNA modification mechanisms and gene activity during development. Science 1975, 187:226-232.
31. Tucker K.L., Beard C., Dausmann J., Jackson-Grusby L., Laird P.W., Lei H., Li E., Jaenisch R. Germ-line passage is required for establishment of methylation and expression patterns of imprinted but not of nonimprinted genes. Genes Dev. 1996, 10:1008-1020.
32. Li E., Beard C., Jaenisch R. Role for DNA methylation in genomic imprinting. Nature 1993, 366:362-365.
33. Singer-Sam J., Riggs A.D. X chromosome inactivation and DNA methylation. EXS 1993, 64:358-384.
34. Yoder J.A., Walsh C.P., Bestor T.H. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 1997, 13:335-340.
35. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
36. Carbone R., Botrugno O.A., Ronzoni S., Insinga A., Di Croce L., Pelicci P.G., Minucci S. Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein. Mol. Cell. Biol. 2006, 26:1288-1296.
37. Stewart M.D., Li J., Wong J. Relationship between histone H3 lysine 9 methylation, transcription repression, and heterochromatin protein 1 recruitment. Mol. Cell. Biol. 2005, 25:2525-2538.
38. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
39. Nakayama T., Takami Y. Participation of histones and histone-modifying enzymes in cell functions through alterations in chromatin structure. J. Biochem. 2001, 129:491-499.
40. Nakayama J., Rice J.C., Strahl B.D., Allis C.D., Grewal S.I. Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science 2001, 292:110-113.
41. Shull J.D., Lachel C.M., Murrin C.R., Pennington K.L., Schaffer B.S., Strecker T.E., Gould K.A. Genetic control of estrogen action in the rat: mapping of QTLs that impact pituitary lactotroph hyperplasia in a BN×ACI intercross. Mamm. Genome 2007, 18:657-669.
42. Cutts J.H., Noble R.L. Estrone-induced mammary tumors in the rat. I. Induction and behavior of tumors. Cancer Res. 1964, 24:1116-1123.
43. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
44. Huang da W., Sherman B.T., Lempicki R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009, 37:1-13.
45. Ertel A., Verghese A., Byers S.W., Ochs M., Tozeren A. Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Mol. Cancer 2006, 5:55.
46. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
47. Pogribny I., Yi P., James S.J. A sensitive new method for rapid detection of abnormal methylation patterns in global DNA and within CpG islands. Biochem. Biophys. Res. Commun. 1999, 262:624-628.
48. Gerdes J., Lemke H., Baisch H., Wacker H.H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 1984, 133:1710-1715.
49. Bravo R. Synthesis of the nuclear protein cyclin (PCNA) and its relationship with DNA replication. Exp. Cell Res. 1986, 163:287-293.
50. Bravo R., Frank R., Blundell P.A., Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 1987, 326:515-517.
51. Chen T., Li E. Establishment and maintenance of DNA methylation patterns in mammals. Curr. Top. Microbiol. Immunol. 2006, 301:179-201.
52. Goll M.G., Bestor T.H. Eukaryotic cytosine methyltransferases. Annu. Rev. Biochem 2005, 74:481-514.
53. Robertson K.D., Uzvolgyi E., Liang G., Talmadge C., Sumegi J., Gonzales F.A., Jones P.A. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999, 27:2291-2298.
54. Liang G., Chan M.F., Tomigahara Y., Tsai Y.C., Gonzales F.A., Li E., Laird P.W., Jones P.A. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol. Cell. Biol. 2002, 22:480-491.
55. Kimura H., Shiota K. Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1. J. Biol. Chem. 2003, 278:4806-4812.
56. Jones P.L., Veenstra G.J., Wade P.A., Vermaak D., Kass S.U., Landsberger N., Strouboulis J., Wolffe A.P. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 1998, 19:187-191.
57. Nan X., Ng H.H., Johnson C.A., Laherty C.D., Turner B.M., Eisenman R.N., Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393:386-389.
58. Pogribny I.P., Tryndyak V.P., Muskhelishvili L., Rusyn I., Ross S.A. Methyl deficiency, alterations in global histone modifications, and carcinogenesis. J. Nutr. 2007, 137:216S-222S.
59. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., Morey L., Van Eynde A., Bernard D., Vanderwinden J.M., Bollen M., Esteller M., Di Croce L., de Launoit Y., Fuks F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874.
60. Bird A.P., Wolffe A.P. Methylation-induced repression - belts, braces, and chromatin. Cell 1999, 99:451-454.
61. Freitag M., Selker E.U. Controlling DNA methylation: many roads to one modification. Curr. Opin. Genet. Dev. 2005, 15:191-199.
62. Lehnertz B., Ueda Y., Derijck A.A., Braunschweig U., Perez-Burgos L., Kubicek S., Chen T., Li E., Jenuwein T., Peters A.H. Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr. Biol. 2003, 13:1192-1200.
63. Santos-Rosa H., Schneider R., Bannister A.J., Sherriff J., Bernstein B.E., Emre N.C., Schreiber S.L., Mellor J., Kouzarides T. Active genes are tri-methylated at K4 of histone H3. Nature 2002, 419:407-411.
64. Peters A.H., Kubicek S., Mechtler K., O'Sullivan R.J., Derijck A.A., Perez-Burgos L., Kohlmaier A., Opravil S., Tachibana M., Shinkai Y., Martens J.H., Jenuwein T. Partitioning and plasticity of repressive histone methylation states in mammalian chromatin. Mol. Cell 2003, 12:1577-1589.
65. Liang G., Lin J.C., Wei V., Yoo C., Cheng J.C., Nguyen C.T., Weisenberger D.J., Egger G., Takai D., Gonzales F.A., Jones P.A. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:7357-7362.
66. Guenther M.G., Levine S.S., Boyer L.A., Jaenisch R., Young R.A. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 2007, 130:77-88.
67. Garcia-Ramirez M., Rocchini C., Ausio J. Modulation of chromatin folding by histone acetylation. J. Biol. Chem. 1995, 270:17923-17928.
68. Wang X., He C., Moore S.C., Ausio J. Effects of histone acetylation on the solubility and folding of the chromatin fiber. J. Biol. Chem. 2001, 276:12764-12768.
69. Tse C., Sera T., Wolffe A.P., Hansen J.C. Disruption of higher-order folding by core histone acetylation dramatically enhances transcription of nucleosomal arrays by RNA polymerase III. Mol. Cell. Biol. 1998, 18:4629-4638.
70. Fletcher T.M., Hansen J.C. Core histone tail domains mediate oligonucleosome folding and nucleosomal DNA organization through distinct molecular mechanisms. J. Biol. Chem. 1995, 270:25359-25362.
71. Sarg B., Koutzamani E., Helliger W., Rundquist I., Lindner H.H. Postsynthetic trimethylation of histone H4 at lysine 20 in mammalian tissues is associated with aging. J. Biol. Chem. 2002, 277:39195-39201.
72. Ma P., Schultz R.M. Histone deacetylase 1 (HDAC1) regulates histone acetylation, development, and gene expression in preimplantation mouse embryos. Dev. Biol. 2008, 319:110-120.
73. He G., Margolis D.M. Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol. Cell. Biol. 2002, 22:2965-2973.
74. Hassig C.A., Tong J.K., Fleischer T.C., Owa T., Grable P.G., Ayer D.E., Schreiber S.L. A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:3519-3524.
75. Fujii S., Ito K., Ito Y., Ochiai A. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J. Biol. Chem. 2008, 283:17324-17332.
76. Nuytten M., Beke L., Van Eynde A., Ceulemans H., Beullens M., Van Hummelen P., Fuks F., Bollen M. The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing. Oncogene 2008, 27:1449-1460.
77. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., Ghosh D., Sewalt R.G., Otte A.P., Hayes D.F., Sabel M.S., Livant D., Weiss S.J., Rubin M.A., Chinnaiyan A.M. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:11606-11611.
78. Markiewski M.M., Nilsson B., Ekdahl K.N., Mollnes T.E., Lambris J.D. Complement and coagulation: strangers or partners in crime?. Trends Immunol. 2007, 28:184-192.
79. Walport M.J. Complement. First of two parts. N. Engl. J. Med. 2001, 344:1058-1066.
80. Walport M.J. Complement. Second of two parts. N. Engl. J. Med. 2001, 344:1140-1144.
81. Donovan F.M., Cunningham D.D. Signaling pathways involved in thrombin-induced cell protection. J. Biol. Chem. 1998, 273:12746-12752.
82. Rutkowski M.J., Sughrue M.E., Kane A.J., Mills S.A., Parsa A.T. Cancer and the complement cascade. Mol. Cancer Res. 2010, 8:1453-1465.
83. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr. Opin. Genet. Dev. 2008, 18:11-18.
84. Kohl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol. Immunol. 2001, 38:175-187.
85. Markiewski M.M., DeAngelis R.A., Benencia F., Ricklin-Lichtsteiner S.K., Koutoulaki A., Gerard C., Coukos G., Lambris J.D. Modulation of the antitumor immune response by complement. Nat. Immunol. 2008, 9:1225-1235.
86. Cybulsky M.I., Chan M.K., Movat H.Z. Acute inflammation and microthrombosis induced by endotoxin, interleukin-1, and tumor necrosis factor and their implication in gram-negative infection. Lab. Invest. 1988, 58:365-378.
87. Edwards R.L., Rickles F.R., Cronlund M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J. Lab. Clin. Med. 1981, 98:917-928.
88. Loreto M.F., De Martinis M., Corsi M.P., Modesti M., Ginaldi L. Coagulation and cancer: implications for diagnosis and management. Pathol. Oncol. Res. 2000, 6:301-312.
89. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
90. Mantovani A., Muzio M., Garlanda C., Sozzani S., Allavena P. Macrophage control of inflammation: negative pathways of regulation of inflammatory cytokines. Novartis Found. Symp. 2001, 234:120-131. [discussion 131-125].
91. Rubin J.B. Chemokine signaling in cancer: one hump or two?. Semin. Cancer Biol. 2009, 19:116-122.
92. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol. 2004, 14:171-179.
93. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
94. Ager E.I., Neo J., Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis 2008, 29:1675-1684.
95. Deshayes F., Nahmias C. Angiotensin receptors: a new role in cancer?. Trends Endocrinol. Metab. 2005, 16:293-299.
96. Pupilli C., Lasagni L., Romagnani P., Bellini F., Mannelli M., Misciglia N., Mavilia C., Vellei U., Villari D., Serio M. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J. Am. Soc. Nephrol. 1999, 10:245-255.
97. Fujita M., Hayashi I., Yamashina S., Itoman M., Majima M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem. Biophys. Res. Commun. 2002, 294:441-447.
98. Vinson G.P., Barker S., Puddefoot J.R. The renin-angiotensin system in the breast and breast cancer. Endocr. Relat. Cancer 2012, 19:R1-R19.
99. Walczak R., Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J. Lipid Res. 2002, 43:177-186.
100. Tontonoz P., Singer S., Forman B.M., Sarraf P., Fletcher J.A., Fletcher C.D., Brun R.P., Mueller E., Altiok S., Oppenheim H., Evans R.M., Spiegelman B.M. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:237-241.
101. DuBois R.N., Gupta R., Brockman J., Reddy B.S., Krakow S.L., Lazar M.A. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis 1998, 19:49-53.
102. Saez E., Rosenfeld J., Livolsi A., Olson P., Lombardo E., Nelson M., Banayo E., Cardiff R.D., Izpisua-Belmonte J.C., Evans R.M. PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev. 2004, 18:528-540.
103. Lukashev M.E., Werb Z. ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 1998, 8:437-441.
104. Nagano M., Hoshino D., Koshikawa N., Akizawa T., Seiki M. Turnover of focal adhesions and cancer cell migration. Int. J. Cell Biol. 2012, 2012:310616.
105. D'Ardenne A.J., Richman P.I., Horton M.A., McAulay A.E., Jordan S. Co-ordinate expression of the alpha-6 integrin laminin receptor sub-unit and laminin in breast cancer. J. Pathol. 1991, 165:213-220.
106. Howeedy A.A., Virtanen I., Laitinen L., Gould N.S., Koukoulis G.K., Gould V.E. Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Lab. Invest. 1990, 63:798-806.
107. Ungefroren H., Sebens S., Seidl D., Lehnert H., Hass R. Interaction of tumor cells with the microenvironment. Cell Commun. Signal. 2011, 9:18.
108. Ben-Ze'ev A. Cytoskeletal and adhesion proteins as tumor suppressors. Curr. Opin. Cell Biol. 1997, 9:99-108.
109. Lochter A., Bissell M.J. Involvement of extracellular matrix constituents in breast cancer. Semin. Cancer Biol. 1995, 6:165-173.
110. Kauppila S., Stenback F., Risteli J., Jukkola A., Risteli L. Aberrant type I and type III collagen gene expression in human breast cancer in vivo. J. Pathol. 1998, 186:262-268.
111. Ramos D.M., Berston E.D., Kramer R.H. Analysis of integrin receptors for laminin and type IV collagen on metastatic B16 melanoma cells. Cancer Res. 1990, 50:728-734.
112. Stein T., Cosimo E., Yu X., Smith P.R., Simon R., Cottrell L., Pringle M.A., Bell A.K., Lattanzio L., Sauter G., Lo Nigro C., Crook T., Machesky L.M., Gusterson B.A. Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. Am. J. Pathol. 2010, 177:2323-2333.
113. Akashi T., Ito E., Eishi Y., Koike M., Nakamura K., Burgeson R.E. Reduced expression of laminin alpha 3 and alpha 5 chains in non-small cell lung cancers. Jpn. J. Cancer Res. 2001, 92:293-301.
114. Ahmed N., Riley C., Rice G., Quinn M. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment. Clin. Exp. Metastasis 2005, 22:391-402.
115. Martin K.J., Kwan C.P., Nagasaki K., Zhang X., O'Hare M.J., Kaelin C.M., Burgeson R.E., Pardee A.B., Sager R. Down-regulation of laminin-5 in breast carcinoma cells. Mol. Med. 1998, 4:602-613.
116. Sathyanarayana U.G., Padar A., Huang C.X., Suzuki M., Shigematsu H., Bekele B.N., Gazdar A.F. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma. Clin. Cancer Res. 2003, 9:6389-6394.
117. Clapper M.L., Szarka C.E. Glutathione S-transferases - biomarkers of cancer risk and chemopreventive response. Chem. Biol. Interact. 1998, 111-112:377-388.
118. Grubben M.J., Nagengast F.M., Katan M.B., Peters W.H. The glutathione biotransformation system and colorectal cancer risk in humans. Scand. J. Gastroenterol. Suppl. 2001, 6:68-76.
119. Gromadzinska J., Wasowicz W., Andrijewski M., Sklodowska M., Quispe O.Z., Wolkanin P., Olborski B., Pluzanska A. Glutathione and glutathione metabolizing enzymes in tissues and blood of breast cancer patients. Neoplasma 1997, 44:45-51.
120. Perquin M., Oster T., Maul A., Froment N., Untereiner M., Bagrel D. The glutathione-related detoxification system is increased in human breast cancer in correlation with clinical and histopathological features. J. Cancer Res. Clin. Oncol. 2001, 127:368-374.
121. Wilkinson J.t., Clapper M.L. Detoxication enzymes and chemoprevention. Proc. Soc. Exp. Biol. Med. 1997, 216:192-200.
122. van der Hel O.L., Bueno-de-Mesquita H.B., van Gils C.H., Roest M., Slothouber B., Grobbee D.E., Peeters P.H. Cumulative genetic defects in carcinogen metabolism may increase breast cancer risk (The Netherlands). Cancer Causes Control 2005, 16:675-681.
123. Hayes J.D., Pulford D.J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 1995, 30:445-600.
124. Moscow J.A., Townsend A.J., Cowan K.H. Elevation of pi class glutathione S-transferase activity in human breast cancer cells by transfection of the GST pi gene and its effect on sensitivity to toxins. Mol. Pharmacol. 1989, 36:22-28.
125. Townsend D.M., Tew K.D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003, 22:7369-7375.
126. Morrow C.S., Diah S., Smitherman P.K., Schneider E., Townsend A.J. Multidrug resistance protein and glutathione S-transferase P 1-1 act in synergy to confer protection from 4-nitroquinoline 1-oxide toxicity. Carcinogenesis 1998, 19:109-115.
127. Perra A., Pibiri M., Sulas P., Simbula G., Ledda-Columbano G.M., Columbano A. Alpha-lipoic acid promotes the growth of rat hepatic pre-neoplastic lesions in the choline-deficient model. Carcinogenesis 2008, 29:161-168.
128. Steinmetz K.L., Pogribny I.P., James S.J., Pitot H.C. Hypomethylation of the rat glutathione S-transferase pi (GSTP) promoter region isolated from methyl-deficient livers and GSTP-positive liver neoplasms. Carcinogenesis 1998, 19:1487-1494.
129. Huang J., Tan P.H., Thiyagarajan J., Bay B.H. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod. Pathol. 2003, 16:558-565.
130. Saleh E.M., El-Awady R.A., Abdel Alim M.A., Abdel Wahab A.H. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells. Cell Biochem. Biophys. 2009, 55:95-105.
131. Miyara H., Hida T., Nishida K., Takahashi T., Sugiura T., Ariyoshi Y., Morishita M., Ueda R. Modification of chemo-radiosensitivity of a human lung cancer cell line by introduction of the glutathione S-transferase pi gene. Jpn. J. Clin. Oncol. 1996, 26:1-5.
132. Choi J.Y., Nowell S.A., Blanco J.G., Ambrosone C.B. The role of genetic variability in drug metabolism pathways in breast cancer prognosis. Pharmacogenomics 2006, 7:613-624.
133. Wright A.T., Cravatt B.F. Chemical proteoamic probes for profiling cytochrome p450 activities and drug interactions in vivo. Chem. Biol. 2007, 14:1043-1051.
134. Doehmer J., Goeptar A.R., Vermeulen N.P. Cytochromes P450 and drug resistance. Cytotechnology 1993, 12:357-366.
135. Rochat B. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin. Pharmacokinet. 2005, 44:349-366.
136. Ruggero D., Pandolfi P.P. Does the ribosome translate cancer?. Nat. Rev. Cancer 2003, 3:179-192.
137. Boisvert F.M., van Koningsbruggen S., Navascues J., Lamond A.I. The multifunctional nucleolus. Nat. Rev. Mol. Cell Biol. 2007, 8:574-585.
138. Amsterdam A., Sadler K.C., Lai K., Farrington S., Bronson R.T., Lees J.A., Hopkins N. Many ribosomal protein genes are cancer genes in zebrafish. PLoS Biol. 2004, 2:E139.
139. Hannan K.M., Sanij E., Hein N., Hannan R.D., Pearson R.B. Signaling to the ribosome in cancer - it is more than just mTORC1. IUBMB Life 2011, 63:79-85.
140. Montanaro L., Trere D., Derenzini M. Nucleolus, ribosomes, and cancer. Am. J. Pathol. 2008, 173:301-310.
141. Belin S., Beghin A., Solano-Gonzalez E., Bezin L., Brunet-Manquat S., Textoris J., Prats A.C., Mertani H.C., Dumontet C., Diaz J.J. Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells. PLoS ONE 2009, 4:e7147.
142. Henry J.L., Coggin D.L., King C.R. High-level expression of the ribosomal protein L19 in human breast tumors that overexpress erbB-2. Cancer Res. 1993, 53:1403-1408.
143. Bullwinkel J., Baron-Luhr B., Ludemann A., Wohlenberg C., Gerdes J., Scholzen T. Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J. Cell. Physiol. 2006, 206:624-635.
144. Aaltomaa S., Lipponen P., Papinaho S., Kosma V.M. Mast cells in breast cancer. Anticancer Res. 1993, 13:785-788.
145. Malkas L.H., Herbert B.S., Abdel-Aziz W., Dobrolecki L.E., Liu Y., Agarwal B., Hoelz D., Badve S., Schnaper L., Arnold R.J., Mechref Y., Novotny M.V., Loehrer P., Goulet R.J., Hickey R.J. A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:19472-19477.
146. Bagnyukova T.V., Pogribny I.P., Muskhelishvili L., Tryndyak V.P., Beland F.A. The role of epigenetic events in genotoxic hepatocarcinogenesis induced by 2-acetylaminofluorene. Mutat. Res. 2010.
147. Bagnyukova T.V., Tryndyak V.P., Montgomery B., Churchwell M.I., Karpf A.R., James S.R., Muskhelishvili L., Beland F.A., Pogribny I.P. Genetic and epigenetic changes in rat preneoplastic liver tissue induced by 2-acetylaminofluorene. Carcinogenesis 2008, 29:638-646.
148. Bachman A.N., Phillips J.M., Goodman J.I. Phenobarbital induces progressive patterns of GC-rich and gene-specific altered DNA methylation in the liver of tumor-prone B6C3F1 mice. Toxicol. Sci. 2006, 91:393-405.
149. Kovalchuk O., Tryndyak V.P., Montgomery B., Boyko A., Kutanzi K., Zemp F., Warbritton A.R., Latendresse J.R., Kovalchuk I., Beland F.A., Pogribny I.P. Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifications and aberrant microRNA expression. Cell Cycle 2007, 6:2010-2018.
150. Rauch T.A., Zhong X., Wu X., Wang M., Kernstine K.H., Wang Z., Riggs A.D., Pfeifer G.P. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:252-257.
151. Lin C.H., Hsieh S.Y., Sheen I.S., Lee W.C., Chen T.C., Shyu W.C., Liaw Y.F. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res. 2001, 61:4238-4243.
152. Jackson K., Yu M.C., Arakawa K., Fiala E., Youn B., Fiegl H., Muller-Holzner E., Widschwendter M., Ehrlich M. DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol. Ther. 2004, 3:1225-1231.
153. Nakagawa T., Kanai Y., Ushijima S., Kitamura T., Kakizoe T., Hirohashi S. DNA hypomethylation on pericentromeric satellite regions significantly correlates with loss of heterozygosity on chromosome 9 in urothelial carcinomas. J. Urol. 2005, 173:243-246.
154. Watts G.S., Futscher B.W., Holtan N., Degeest K., Domann F.E., Rose S.L. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med. Genomics 2008, 1:47.
155. Kim Y.I., Giuliano A., Hatch K.D., Schneider A., Nour M.A., Dallal G.E., Selhub J., Mason J.B. Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma. Cancer 1994, 74:893-899.
156. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., Leonhardt H., Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science 2003, 300:489-492.
157. Trinh B.N., Long T.I., Nickel A.E., Shibata D., Laird P.W. DNA methyltransferase deficiency modifies cancer susceptibility in mice lacking DNA mismatch repair. Mol. Cell. Biol. 2002, 22:2906-2917.
158. Okano M., Bell D.W., Haber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257.
159. Li E., Bestor T.H., Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992, 69:915-926.
160. Niculescu M.D., Zeisel S.H. Diet, methyl donors and DNA methylation: interactions between dietary folate, methionine and choline. J. Nutr. 2002, 132:2333S-2335S.
161. Chiang P.K., Gordon R.K., Tal J., Zeng G.C., Doctor B.P., Pardhasaradhi K., McCann P.P. S-Adenosylmethionine and methylation. FASEB J. 1996, 10:471-480.
162. Ulrey C.L., Liu L., Andrews L.G., Tollefsbol T.O. The impact of metabolism on DNA methylation. Hum. Mol. Genet. 2005, 14(Spec No. 1):R139-R147.
163. Zeisel S.H. Genetic polymorphisms in methyl-group metabolism and epigenetics: lessons from humans and mouse models. Brain Res. 2008, 1237:5-11.
164. Arita K., Ariyoshi M., Tochio H., Nakamura Y., Shirakawa M. Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism. Nature 2008, 455:818-821.
165. Szyf M. The DNA methylation machinery as a therapeutic target. Curr. Drug Targets 2000, 1:101-118.
166. Szyf M., Knox D.J., Milutinovic S., Slack A.D., Araujo F.D. How does DNA methyltransferase cause oncogenic transformation?. Ann. N. Y. Acad. Sci. 2000, 910:156-174. [discussion 175-157].
167. Linhart H.G., Lin H., Yamada Y., Moran E., Steine E.J., Gokhale S., Lo G., Cantu E., Ehrich M., He T., Meissner A., Jaenisch R. Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev. 2007, 21:3110-3122.
168. Roll J.D., Rivenbark A.G., Jones W.D., Coleman W.B. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol. Cancer 2008, 7:15.
169. Tonini T., Bagella L., D'Andrilli G., Claudio P.P., Giordano A. Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Oncogene 2004, 23:4930-4937.
170. Pietersen A.M., Horlings H.M., Hauptmann M., Langerod A., Ajouaou A., Cornelissen-Steijger P., Wessels L.F., Jonkers J., van de Vijver M.J., van Lohuizen M. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res. 2008, 10:R109.
171. Raaphorst F.M., Meijer C.J., Fieret E., Blokzijl T., Mommers E., Buerger H., Packeisen J., Sewalt R.A., Otte A.P., van Diest P.J. Poorly differentiated breast carcinoma is associated with increased expression of the human Polycomb group EZH2 gene. Neoplasia 2003, 5:481-488.
172. Bachmann I.M., Halvorsen O.J., Collett K., Stefansson I.M., Straume O., Haukaas S.A., Salvesen H.B., Otte A.P., Akslen L.A. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 2006, 24:268-273.
173. Collett K., Eide G.E., Arnes J., Stefansson I.M., Eide J., Braaten A., Aas T., Otte A.P., Akslen L.A. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin. Cancer Res. 2006, 12:1168-1174.